To the editor:

*Kidney International* recently published 2 series of renal allograft recipients with coronavirus disease 2019 (COVID-19) infection including different approaches to maintenance immunosuppression. Although Alberici *et al.* [@bib1] report withdrawal of baseline immunosuppression in 20 patients with COVID-19 pneumonia and mainly continuation with methylprednisolone, Banerjee *et al.* [@bib2] pursued more-gentle reduction of immunosuppression with mainly discontinuation of the antimetabolite in 7 patients with COVID-19 infections of varying severity. However, in 2 of the 7 patients, the calcineurin inhibitor tacrolimus was additionally stopped because of severe respiratory distress syndrome. The corresponding editorial[@bib3] suggests switching to the calcineurin inhibitor cyclosporine as a possible further approach for future exploration, as *in vitro* data report suppression of viral replication for various coronaviruses at noncytotoxic concentrations regardless of immunosuppressive effects of cyclosporine.[@bib4] In line with this suggestion, we report the first renal allograft recipient converted to cyclosporine during COVID-19 infection. The 45-year-old male had been transplanted 16 years ago. His immunosuppression consisted of only the antimetabolite mycophenolate mofetil. On admission, the patient presented with typical symptoms of COVID-19 pneumonia including fever, cough, dyspnea, and crazy paving pattern in computed tomography scan. The main characteristics are summarized in [Table 1](#tbl1){ref-type="table"} . The therapeutic regimen consisted of withdrawal of the antimetabolite, conversion to low-dose steroid, and introduction of low-dose cyclosporine, azithromycin, and hydroxychloroquine. He required mechanical ventilation for 4 days until his general condition improved significantly, and he was able to be discharged after 17 days with stable allograft function. Therefore, switching to a cyclosporine-based immunosuppression may represent another therapeutic option in the case of COVID-19 infection following kidney transplantation.Table 1(According to Banerjee *et al.*[@bib2]): clinical characteristics, outcome, and blood parameters of first kidney transplant patient converted to cyclosporine during COVID-19 infectionPatientAge/sexTx dateComorbiditiesRespiratory and renal involvementBaseline creatinine (eGFR ml/min per 1.73 m^2^)Baseline immunosuppression and treatmentACEI or ARBOutcome145 yr/M2004HT/ hypercholisterinemiaYes, ARDS + AKI (without need for RRT)124--141 (51--59)MMF\
MMF stopped and switch to CyA/PredNoDischarged from ITU,\
now at home,\
full recovery**Cont. with patientWhite cell count (×10**^**9**^**/l) (3.9--9.8)Lymphocyte count (×10**^**9**^**/l) (1.1--3.2)Serum CRP (mg/l) (\<5)Serum ferritin (μg/l) (30--400)Serum D dimer (μg/l) (0--500)Serum LDH (U/l) (\<249)Serum troponin T (ng/l) (\<14)**17.4 (D1)1.18 (D4)18 (D1),\
289 (D8)2563 (D9)600 (D2),\
8800 (D10)346 (D2),\
634 (D9)\<13[^1]

[^1]: ACEI, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; ARDS, acute respiratory distress syndrome; Cont., continued; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CyA, cyclosporine A; D, day after admission; D1, day of admission; eGFR, estimated glomerular filtration rate; HT, hypertension; ITU, intensive therapy unit; LDH, lactate dehydrogenase; M, male; MMF, mycophenolate mofetil; Pred, prednisolone; RRT, renal replacement therapy; Tx, treatment.
